Providing you the best range of pemigatinib 4.5 mg tablets with effective & timely delivery.
₹ 4265 / Box Get Latest Price
| Brand Name | LuciPem |
| Form | Tablet |
| Storage Condition | 20 DegreeC to 25 DegreeC |
| Prescription/Non prescription | Prescription |
| Composition | Pemigatinib |
| Strength | 4.5 mg |
| Packaging Size | 14 Tablets |
| Manufacturer | Lucius Pharmaceuticals, Laos |
| Packaging Type | Box |
| Treatment | A rare cancer of the bile ducts |
| Shelf Life | 24 Months |
| Manufacturing Unit | Laos |
Minimum order quantity: 10 Box
Lucipem 4.5mg is a targeted cancer therapy that contains Pemigatinib, a selective inhibitor of fibroblast growth factor receptors (FGFR). Developed for precision oncology, it is primarily used in the treatment of cholangiocarcinoma (a rare cancer of the bile ducts) and other tumors associated with FGFR genetic alterations. Lucipem represents a significant advancement in personalized cancer treatment by offering an option based on specific genetic markers.
What is Lucipem 4.5mg (Pemigatinib)?Lucipem 4.5mg is an oral anticancer drug formulated with Pemigatinib, a small molecule kinase inhibitor. It is marketed for patients whose cancers exhibit FGFR2 fusions or rearrangements. Approved by regulatory bodies such as the US FDA under accelerated pathways, Pemigatinib is used when the cancer is unresectable (cannot be removed by surgery) or has metastasized (spread to other organs).
How it Works / Mechanism of ActionPemigatinib works by inhibiting the activity of FGFR1, FGFR2, and FGFR3—proteins that play a vital role in cell growth, survival, and differentiation.Cancer and unchecked cell proliferation can result from FGFR gene fusions or rearrangements. By selectively binding to these receptors, Pemigatinib blocks downstream signaling pathways such as MAPK, PI3K-AKT, and PLCγ, which are responsible for tumor growth. This inhibition suppresses tumor progression and induces cell death in cancer cells with FGFR abnormalities.
How to Use / IndicationsLucipem 4.5mg is indicated for:
FGFR2 fusion or rearrangement in an incurable locally progressed or metastatic cholangiocarcinoma, as verified by a diagnostic test approved by the FDA.
It is also being studied and used off-label in urothelial carcinoma, glioblastoma, and other rare FGFR-driven tumors in clinical settings.
Standard Dosage:
The recommended dose is 13.5 mg once daily for 14 days, followed by 7 days off in a 21-day cycle.
Lucipem 4.5mg tablets are usually taken in a divided dose (e.g., 3 tablets) to reach 13.5 mg per day.
Administration Tips:
Take it at the same time every day.
Can be taken with or without food.
Swallow tablets whole with water. Do not crush or split.
Avoid taking with grapefruit or grapefruit juice (may alter drug metabolism).
Hyperphosphatemia
Nail changes
Dry mouth
Fatigue
Hair thinning or loss
Diarrhea or constipation
Loss of appetite
Eye disorders (e.g., retinal detachment, blurred vision)
Electrolyte imbalances (especially phosphate, calcium)
Kidney or liver dysfunction
Stomatitis (inflammation of the mouth)
Non-healing mouth ulcers
Skin rashes or hand-foot syndrome
Store Lucipem 4.5mg tablets at room temperature (20°C to 25°C).
Protect from moisture and direct light.
Keep it in the original packaging until use.
Keep out of reach of children.
Do not use expired medication.
Lucipem offers numerous benefits, especially for patients with no other targeted options:
Precision Medicine
Oral Administration
Disease Control
Tolerability
Hope in Rare Cancers
Tushar Ghanshyambhai Kalathiya (CEO)
Leaf Pharma
Ground Floor Plot No-19 Opp. Govindaji Hall, Dabholi Road, OPP. GOVINDAJI HALL, Surat - 395004, Gujarat, India